# Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study

> **NCT07527182** · NA · COMPLETED · sponsor: **Didier Menard** · enrollment: 277 (actual)

## Conditions studied

- Malaria (Plasmodium Falciparum)
- Drug Resistance
- Artemisinin-resistant
- Ethiopia

## Interventions

- **DRUG:** Artemether-Lumefantrine Tab 20-120mg

## Key facts

- **NCT ID:** NCT07527182
- **Lead sponsor:** Didier Menard
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-01
- **Primary completion:** 2025-10-30
- **Final completion:** 2026-04-07
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527182, "Artemisinin Partial Resistance in Ethiopian Plasmodium Falciparum: A Multisite Clinical, Molecular and In Vitro Study". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07527182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*